SGLT2 Inhibitors Cut Kidney Disease Progression by a Third
A pooled analysis of 90,000 patients confirms what nephrologists have suspected: this drug class is doing more than lowering glucose.
Anatomical illustration of human kidneys on a soft blue background.
Few drug classes have rewritten guidelines as quickly as SGLT2 inhibitors. A new pooled analysis of 13 trials and roughly 90,000 patients tightens the case for routine use in chronic kidney disease.
The headline
Kidney disease progression — defined as a 50% drop in eGFR, end-stage kidney disease, or renal death — fell by 33% across the pooled population. The effect was consistent in diabetic and non-diabetic patients.
Why this matters
Chronic kidney disease has been one of medicine's most stubborn slow burns. For decades, ACE inhibitors and ARBs were the only interventions with meaningful effect on progression. SGLT2 inhibitors now sit alongside them.
The class went from a glucose-lowering drug to a heart drug to a kidney drug in under a decade.
Caveats
The absolute risk reduction depends heavily on baseline kidney function. Patients with already-significant disease benefit more in absolute terms. Genitourinary infections remain the most common adverse event.
What changes for primary care
Expect SGLT2 inhibitors to appear earlier in the CKD treatment algorithm in updated guidelines next year. The case for starting them in patients with proteinuria — regardless of diabetes status — is now strong.
